Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + gemcitabine + irinotecan for platinum‑resistant ovarian cancer
jRCTs031220424Phase 2Suspended
- Sponsor
- Clinical Research Initiation Fund
- Start
- Oct 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, gemcitabine and irinotecan in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Clinical Research Initiation Fund. Primary endpoint: Progression-free survival. Started Oct 2022; status: suspended.
02
Drugs
bevacizumabgemcitabineirinotecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCTs031220424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220424.